Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07371650
PHASE2

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza

Sponsor: Traws Pharma, Inc.

View on ClinicalTrials.gov

Summary

This is an early-stage clinical trial to determine a safe and effective dose for Tivoxavir Marboxil (TRX-100) in patients with mild to moderate Influenza. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.

Official title: A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate the Safety and Efficacy of Different Oral Doses of TRX-100 and Standard of Care in Participants With Influenza

Key Details

Gender

All

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

105

Start Date

2025-12-15

Completion Date

2027-01

Last Updated

2026-03-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

TRX-100

CEN inhibitor, dosage form - capsules, dosing regimen - QD

DRUG

Standard of Care (SOC)

Standard of Care Influenza Antiviral therapy

Locations (1)

Novatrials

Charlestown, New South Wales, Australia